Twist Bioscience CORP Form 4 insider transactions

Adam Laponis, CFO of Twist Bioscience, sold 2,542 shares of common stock on April 9, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Patrick John Finn, President and COO of Twist Bioscience, sold 206 shares of common stock on April 2, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 140 shares of common stock on April 2, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Emily Leproust, CEO of Twist Bioscience, sold 492 shares of common stock on April 2, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold 230 shares of common stock on March 20, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 291 shares of common stock on March 20, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Emily Leproust, CEO of Twist Bioscience, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units on March 20, 2025.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 918 shares of common stock on March 6, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Emily Leproust, CEO of Twist Bioscience, sold 2,402 shares of common stock at $40.913 per share to cover tax withholding obligations related to vesting Restricted Stock Units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, sold 241 shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Dennis Cho, a Senior Vice President at Twist Bioscience, sold shares to cover tax withholding obligations related to vesting Restricted Stock Units.

Twist Bioscience's President and COO, Patrick John Finn, sold shares to cover tax withholding obligations related to vested Restricted Stock Units.

Paula Green, SVP of Human Resources at Twist Bioscience, reports selling shares to cover tax withholding obligations related to vesting restricted stock units.

Adam Laponis, CFO of Twist Bioscience, sold 918 shares of common stock on February 21, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Emily Leproust, CEO of Twist Bioscience, sold 2,790 shares of common stock on February 21, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Robert Chess, a director at Twist Bioscience Corp, sold 2,940 shares of common stock on February 7, 2025, to cover tax liabilities related to vesting Restricted Stock Units.

Director Keith Crandell reports acquisition of Twist Bioscience shares through an equity award and discloses beneficial ownership.

Director Jan Johannessen reports acquiring 4,472 shares of Twist Bioscience common stock on February 5, 2025, through an equity award.

Director Robert Ragusa reports acquiring and disposing of Twist Bioscience Corp common stock on February 5, 2025.

Director Melissa A. Starovasnik reports acquisition of 4,472 shares of Twist Bioscience common stock and disposal of shares.

Director Robert Chess reports acquiring 4,472 shares of Twist Bioscience Corp stock and beneficially owning 21,113 shares directly and 42,528 indirectly through a trust.

Director Chan Nelson C acquired 4,472 shares of Twist Bioscience Corp common stock on February 5, 2025, and disposed of 28,156 shares.

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp, sold 185 shares of common stock on February 3, 2025, to cover tax withholding obligations related to vesting Restricted Stock Units.

Emily Leproust, CEO of Twist Bioscience, sold 5,200 shares of common stock on February 3, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Paula Green, SVP of Human Resources at Twist Bioscience, sold 1,259 shares of common stock on February 3, 2025, to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Patrick John Finn, President and COO of Twist Bioscience, sold 2,845 shares of common stock on February 3, 2025, to cover tax withholding obligations related to vesting restricted stock units.